[Several issues and considerations in the clinical diagnosis and treatment of immune checkpoint inhibitor-associated liver injury].

Abstract

Immune checkpoint inhibitor-associated liver injury is a special type of drug-induced liver injury, and its clinical management has already become an emerging topic in recent years. This article focuses on a series of issues that have attracted much attention in the clinical diagnosis and treatment of immune checkpoint inhibitor-associated liver injury, including the clinical type and severity assessment, the role of liver biopsy, differentiation from autoimmune hepatitis, glucocorticoid dose selection, second-line immunosuppressant selection and timing, opportunistic infection prevention, hormone efficacy prediction, and hormone reduction and course of treatment. In addition, this article analyzes the relevant key points and proposes the current issues at the same time that have not yet been resolved, combined with the latest research progress at home and abroad.